# Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension

> **NCT07641296** · PHASE1 · NOT_YET_RECRUITING · sponsor: **SpyGlass Pharma, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** BIM-DRS Low Dose
- **DRUG:** BIM-DRS High Dose
- **DEVICE:** SpyGlass IOL with silicone pads (no drug)

## Key facts

- **NCT ID:** NCT07641296
- **Lead sponsor:** SpyGlass Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-02-28
- **Final completion:** 2030-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641296, "Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07641296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*